Genmab — December 2016
-
Suverænt link Fafar. Tak for det. Det sender jeg til Lau og Beskos.

-
Vedr. AIHA: 2% af AML-patienter får denne komplikation efter 1. transplantation, og 10% efter 2. transplantation. Er der nogen der har tal på hvor mange AML-patienter der får knoglemarvstransplantation. På kræftens bekæmpelse skriver de "et stigende antal". Og tak for artiklen George.
-
Yesterdays symposium discussed the various treatment options and therapeutic decisions faced by clinicians treating myeloma. It was clear even the experts didn’t always agree on what best practice is, that it is different for each patient and that clinical judgement is needed for each decision.
-

-
Daratumumab indtager atter hovedrolle på ASH http://dagensmedicin.dk/daratumumab-indtager-atter-hovedrolle-paa-ash/
-
Det indledende ASH-satellite symposium om behandlingsmulighederne i alle faser af MM er her: https://www.myeloma.org/videos/ASH-Satellite-Symposium-2016 Hvis man ikke orker alle tre timer kan man spole frem til 2:14:25 hvor Philippe Moreau gennemgår behandlingsmulighederne i relapsed setting (hvor dara jo er godkendt), Og det kan godt afsløres: dara er fuldstændig dominerende.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind